Chinese Distribution Contract Extended for an Additional 4 Years

FOUNTAIN HILLS, Ariz., Feb. 5 /PRNewswire-FirstCall/ -- Sunridge International (OTC Bulletin Board: SNDZ) announced today that they have extended the exclusive distribution agreement with Beijing Vision World Trading Co., Ltd. for an additional 4 years.

"I am very happy to sign this agreement," states G. Richard Smith, CEO of Sunridge International (www.sunridgeint.com). "We have worked closely with Beijing Vision World Trading Co., Ltd. (BV) over the last 3 1/2 years to complete the registration process for Pneumatic Trabeculoplasty, 'PNT' in China."

PNT is a two-minute, noninvasive, cost effective, alternative treatment for glaucoma and ocular hypertension, which was developed and patented by Ophthalmic International (www.oi-pnt.com), Sunridge Internationals wholly owned subsidiary.

"The registration process for a medical device and treatment is very strict in China.  It is a very long, expensive and tedious procedure," states Mr. Smith.  BV has worked tirelessly over the last 3 1/2 years at a tremendous financial cost to its company to compete this process.  They have performed several successful clinical trials at both private and state military hospitals as part of this effort.  With approval expected in the very near future, BV is now concentrating on its marketing efforts.  They have ordered and received delivery on 5 units with a substantial number of disposable rings, to be placed in 5 major hospitals in Beijing.  These hospitals will be used as models for the rest of the country.  They are currently negotiating with a number of companies to act as sub distributors to expand distribution throughout all of China.  They are attending different levels of Academy Conferences and Exhibitions as part of their "PNT" awareness program.  Doctors and distributor personal are being trained.  BV is doing everything possible to ensure the successful marketing of PNT in China.

Mr. Smith goes on to say, "that this is a significant event for OI.  China is a major market for us, with millions of Glaucoma patients.  The fact that a 'PNT' treatment lasts 3-4 months as a rule, with little or no side effects, makes it a very viable treatment for not only for the people of China, but for people everywhere.  We expect that this will prove to be a very profitable market for OI."

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.  Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers, and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.

CONTACT:  Jeff Smith of Sunridge International, +1-480-837-6165, [email protected]

SOURCE Sunridge International